Thus, these results indicate that central administration of AAV-LEAP2 in the ARC does not alter energy metabolism but rather reduces food intake, thereby lowering body weight and is responsible for the resistance to diet-induced obesity and related disorders. Here, LEAP2 is linked to obesity due to melanocortin 4 receptor deficiency.